Advancing a potential multiple myeloma treatment option

Learn how Pfizer’s focus on immunotherapy aims to help people with multiple myeloma

Pfizer is studying a potential treatment for multiple myeloma that uses a person’s immune system to fight off cancer cells.

We are conducting a series of clinical trials, called the MagnetisMM studies, to evaluate the safety and effectiveness of a study medicine called elranatamab (el-ruh-NAH-tuh-mab).

Elranatamab is given as a subcutaneous injection (a needle inserted under the skin in order to deliver the study medicine). It is thought to work by connecting certain immune system cells, known as T-cells, to myeloma cells. Connecting these cells activates the immune cells to kill the myeloma cells.

The MagnetisMM studies will have their own unique requirements for who may participate (eligibility criteria). The requirements may include your stage of multiple myeloma as well as any previous treatments you may have received.

If you or a loved one are considering participating in these studies, find more information in the clinical trials list below.

Find a multiple myeloma clinical trial

Find a Pfizer clinical trial

Refine your search

Show filters

Filter by

Male
Female
  • 50
  • 100
  • 150
  • 200
  • 250+
9 trials found
All (9) Recruiting (8) Not yet recruiting (1)
  • Save search
  • Saved trials
5 trials recruiting
2 trials not yet recruiting
MagnetisMM Clinical Trials
These studies will evaluate the safety and effectiveness of a study medicine, called elranatamab, in people with multiple myeloma.
Multiple Myeloma
MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT05020236
Recruiting
Male or Female
18+ years
440study location(s)
Multiple Myeloma
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
NCT05090566
Recruiting
Male or Female
18+ years
78study location(s)
Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
NCT03530683
Recruiting
Male or Female
18+ years
76study location(s)
Multiple Myeloma
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
NCT05675449
Recruiting
Male or Female
18+ years
2study location(s)
Multiple Myeloma
A Study to Learn About the Study Medicine (Elranatamab) Either Alone or in Combination With Dexamethasone in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment
NCT05014412
Recruiting
Male or Female
18+ years
76study location(s)
Multiple Myeloma
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020
Recruiting
Male or Female
18+ years
28study location(s)
Multiple Myeloma
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416
Recruiting
Male or Female
18+ years
144study location(s)
Lymphoma, Multiple Myeloma
A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies
NCT05567887
Recruiting
Male or Female
18+ years
3study location(s)
Relapse Multiple Myeloma, Refractory Multiple Myeloma
A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases
NCT05742217
May 01, 2023 - Planned start date (Not yet recruiting)
Male or Female
18+ years
1study location(s)

Saved trials

You currently don’t have any saved trials. To save a trial, select the bookmark icon on the result listing.

Contact us

For more information about participation in a Pfizer clinical trial, please email or call the Pfizer Clinical Trial Contact Center at 1-800-887-7002.

About multiple myeloma

Plasma cells are produced in healthy bone marrow. Plasma cells are a type of white blood cell that creates antibodies. These antibodies help your body kill germs and fight infection.

Multiple myeloma is a type of blood cancer that forms in bone marrow. Multiple myeloma is when healthy plasma cells change and grow at a rapid pace. Abnormal (myeloma or cancer) plasma cells overcrowd and/or prevent the growth and creation of healthy plasma cells and other cells within the bone marrow.

Like healthy plasma cells, some myeloma cells create antibodies. However, the antibodies don’t work properly, lowering your body’s ability to fight infection. Abnormal plasma cells also build up in the bones and organs, making it difficult for them to work properly, causing issues such as kidney problems.

Back to top